1Suresh C Tyagi,Lane M Smiley,Vibhas S Mujumdar. Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone[J] 1998,Molecular and Cellular Biochemistry(1-2):107～116
2Boushey CJ,Beresford SA,Omenn GS,et al.A quantitativeassessment of plasma homocysteine as a risk factor for vasculardisease:probable benefits of increasing folic acid intakes[J].JAMA,1995,274:1049-1057.
4Boushey CJ,Beresford SAA,Omenn GS,et al.A quantitative assessment of plasma homocysteine as a risk for vascular disease[J].JAMA,1995,274:1049-1057.
5Morita H,Taguchi J,Kurihara H,et al.Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase(MTHFR)as a risk factor for coronary atrery disease[J].Circulation,1997,95:2032-2036.
6Brattstrom L.Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease[J].Circulation,1997,96:3805-3806.
7Harpel PC,Chang VT,Borth W.Homocystenine and othersulfhydryl compounds enhance the binding of lipoproteina tofibrin:a potential biochemical link between thrombosis,atherogenesis and sulthydryl compound metabolism[J].ProcNatl Acad Sci USA,1992,89:10193-10197.
8Welch GN,Loscalzo J,Homocysteine and arteriosclerosis.N Engl Jmed,1998;338∶1042-1050.
9StangerO,FowlerB,HerrmannW.Folate therapy and in-stentrestenosis[J].NEngl JMed,2004,351:1259-1260.
